cjc1295.prescribed

CITATION INDEX

CJC-1295 References

The indexed primary literature, the regulatory file, and the anti-doping list — every citation referenced across the platform overview.

Every numbered citation marker across the CJC-1295 specification on this site resolves to one of the entries below. The list combines the published phase-1 pharmacokinetic trials of CJC-1295 with DAC [1][2][16], the GHRH-knockout preclinical work [3], the proteomic follow-on [4], the analytical-chemistry characterization of a seized doping-market preparation [5], the GHRH-biochemistry and GHRP-pharmacology papers that frame the mechanism [6][7][8][9][10], the comparator-class tesamorelin pivotal trial [11], the WADA Prohibited List [12], the FDA 503A Pharmacy Compounding Advisory Committee briefing document [13], and the public-record account of the phase-2 cardiovascular event [14].

Primary phase-1 human pharmacokinetic trials

References [1] (Teichman 2006 single-ascending-dose), [2] (Ionescu 2006 pulsatility companion), and [16] (Teichman 2006 multi-dose arm) constitute the published phase-1 human evidence base for CJC-1295 with DAC.

Preclinical and biochemistry

References [3] (Alba 2006 GHRH-knockout mouse), [4] (Sackmann-Sala 2009 serum proteomics), [5] (Henninge 2010 analytical-chemistry identification), and [6] (Frohman 1989 DPP-IV inactivation of GHRH 1-29) establish the structural, proteomic, and protease-resistance basis of the GHRH-analog class.

Class comparators and GHRP pairing

References [7] (Raun 1998 ipamorelin selectivity), [8] (Bowers 1990 GHRH + GHRP-6 synergy), [10] (Frohman 1984 sermorelin pharmacokinetics), [11] (Falutz 2010 tesamorelin pivotal), and [15] (Gobburu 1999 ipamorelin healthy-volunteer dose-finding) frame CJC-1295 within the broader GHRH and GHRP pharmacology literature.

Sleep architecture

Reference [9] (Steiger 1992 intranasal GHRH) is the upstream mechanism paper that informs interpretation of GHRH-axis effects on slow-wave sleep.

Regulatory and anti-doping record

References [12] (WADA 2025 Prohibited List), [13] (FDA 2023 Pharmacy Compounding Advisory Committee briefing), and [14] (aidsmap 2006 public-record account of the ConjuChem CL-2002 cardiovascular event) form the regulatory and safety-signal record.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006;91(3):799-805.doi: 10.1210/jc.2005-1536 · https://academic.oup.com/jcem/article/91/3/799/2843281
  2. Ionescu M, Frohman LA. Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.doi: 10.1210/jc.2006-1702 · https://academic.oup.com/jcem/article/91/12/4792/2656274
  3. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294.doi: 10.1152/ajpendo.00201.2006 · https://pubmed.ncbi.nlm.nih.gov/16822960/
  4. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477.doi: 10.1016/j.ghir.2009.03.001 · https://www.sciencedirect.com/science/article/abs/pii/S1096637409000409
  5. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650.doi: 10.1002/dta.158 · https://pubmed.ncbi.nlm.nih.gov/21204297/
  6. Frohman LA, Downs TR, Heimer EP, Felix AM. Degradation of human growth hormone-releasing factor (hGRF 1-29)-NH2 by various peptidases and DPP-IV-mediated inactivation. J Clin Invest. 1989;83(5):1533-1540.doi: 10.1172/JCI114122 · https://www.jci.org/articles/view/114122
  7. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.doi: 10.1530/eje.0.1390552 · https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390
  8. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone-releasing peptide-6 (GHRP-6) stimulates growth hormone secretion synergistically with GHRH in normal subjects. J Clin Endocrinol Metab. 1990;70(4):975-982.doi: 10.1210/jcem-70-4-975 · https://pubmed.ncbi.nlm.nih.gov/2108187/
  9. Steiger A, Guldner J, Hemmeter U, Rothe B, Wiedemann K, Holsboer F. Sleep-promoting effects of growth hormone-releasing hormone in normal men. Neuroendocrinology. 1992;56(4):566-573.doi: 10.1159/000126067 · https://pubmed.ncbi.nlm.nih.gov/1361964/
  10. Frohman LA, Thominet JL, Webb CB, Vance ML, Uderman H, Rivier J, Vale W, Thorner MO. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. J Clin Invest. 1984;73(5):1304-1311.doi: 10.1172/JCI111574 · https://www.jci.org/articles/view/111574
  11. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304.doi: 10.1210/jc.2010-0490 · https://pubmed.ncbi.nlm.nih.gov/20554713/
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard — Prohibited List 2025. WADA-AMA.https://www.wada-ama.org/en/prohibited-list
  13. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting — CJC-1295 bulk drug substance nomination. 2023.https://www.fda.gov/media/183819/download
  14. Carter M. Lipodystrophy study halted after patient death. aidsmap (NAM news report on ConjuChem trial CL-2002). 2006.https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death
  15. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Growth hormone (GH) response to ipamorelin, a new pentapeptidic selective GH secretagogue, in healthy volunteers. Pharm Res. 1999;16(9):1412-1416.doi: 10.1023/A:1018955126402 · https://pubmed.ncbi.nlm.nih.gov/10496658/
  16. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults — multi-dose arm. J Clin Endocrinol Metab. 2006;91(3):799-805.doi: 10.1210/jc.2005-1536 · https://academic.oup.com/jcem/article/91/3/799/2843281
  17. Teichman SL et al., subcutaneous administration route as described in the CJC-1295 phase-1 pharmacokinetic protocol — see reference [1].doi: 10.1210/jc.2005-1536 · https://academic.oup.com/jcem/article/91/3/799/2843281